Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 16,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Completed No phase listed Observational

Magnetic Resonance Imaging:A Window to Anthracycline Toxicity

NCT03211520
View directory record Official record
Conditions
Cardiac Complications
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
9 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

NCT01389024
View directory record Official record
Conditions
Sickle Cell Disease, Stroke
Interventions
Hydroxyurea, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Months to 54 Months
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Not applicable Interventional

Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)

NCT07171684
View directory record Official record
Conditions
Diabetes in Pregnancy, Gestational Diabetes
Interventions
Insulin glargine alone, Insulin glargine + insulin lispro
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Early Phase 1 Interventional

Tirzepatide in Obesity-Driven Endometrial Cancer

NCT07065552
View directory record Official record
Conditions
Endometrial Cancer, Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting No phase listed Observational

Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

NCT05988658
View directory record Official record
Conditions
Acute Kidney Injury, Biomarkers
Interventions
ESTOP - AKI 2.0
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

NCT00257348
View directory record Official record
Conditions
Cervical Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Not applicable Interventional

Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory

NCT03101826
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Listening Project Protocol
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
13 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Brewster, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Massage on the Immune System of Preterm Infants

NCT00317278
View directory record Official record
Conditions
Premature Birth, Stress
Interventions
massage therapy, Sham
Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
28 Weeks to 33 Weeks
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT01313078
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
Interventions
Pegylated L-Asparaginase
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

NCT03695835
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Immunotherapeutic Agents, Ablation
Drug · Device
Lead sponsor
Gary Onik MD
Individual
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT07503808
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions
IDE034
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

NCT06852976
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
0.75% MDI-1228_mesylate gel plus Standard of Care, Standard of Care Alone
Drug · Other
Lead sponsor
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Certolizumab pegol, Placebo
Biological · Drug
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Not applicable Interventional

Tract Closure in PCNL

NCT07668817
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Floseal, Surgicel, Surgiflo, Balloon Tamponade
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Not applicable Interventional Results available

Biofeedback Based Virtual Reality Intervention to Manage Postoperative Pain

NCT04943874
View directory record Official record
Conditions
Pain, Pain, Postoperative, Pain, Acute, Surgery
Interventions
Technology Based Intervention Group 1, Technology Based Intervention Group 2
Device
Lead sponsor
Vanessa Olbrecht
Other
Eligibility
12 Years to 18 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Not listed Phase 4 Interventional

Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

NCT04917718
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Transplant
Interventions
Conversion from IR Tacrolimus to XR Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

PERL Continuous Glucose Monitoring (CGM) Study

NCT03334318
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Mean blood glucose, Blood glucose CV, % time 70-180 mg/dL, % time below 54 mg/dL, % time above 180 mg/dL, % time above 250 mg/dL, MAGE (Mean amplitude of glucose excursions), LBGI (Low Blood Glucose Index), HBGI (High Blood Glucose Index), Allopurinol, Placebo
Other · Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
15
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 4 Interventional Results available

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT01824082
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Perineural infusion [continuous peripheral nerve block(s)]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement

NCT04726085
View directory record Official record
Conditions
Preterm Labor
Interventions
Indomethacin 150mg, Ibuprofen 2400mg
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

The Significance of Funguria in Hospitalized Patients

NCT00787085
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Not listed
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
Not listed
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2008 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

NCT00002943
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 30, 2026, 7:08 AM EDT
Not listed Phase 3 Interventional

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

NCT03897335
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 30, 2026, 7:08 AM EDT